The Tiny Pill That Wants to Dethrone a Blockbuster Drug
A nine-patient trial from an AI-driven startup just produced eczema data that rivals Sanofi's $15 billion blockbuster Dupixent. The catch? It's a once-daily pill, not an injection, and the real tests are just beginning.
Nine patients. Twenty-eight days. And a set of results that just sent a shiver through Sanofi's boardroom.
Enveda Biosciences, a clinical-stage startup most people in biotech have barely heard of, just dropped Phase 1b data for an oral pill called ENV-294 in atopic dermatitis (severe eczema). The numbers look like they belong to a drug that's been on the market for years, not one that's barely out of safety testing. And the target it's aiming at? Dupixent, the injectable blockbuster that pulled in roughly $14.1 billion in global revenue last year.
This is a David-and-Goliath story, except David found his slingshot using artificial intelligence and the chemistry of plants.
A Pill vs. a Needle
Let's set the stage. If you have moderate-to-severe atopic dermatitis, your best options right now fall into two buckets. Bucket one: biologics like Dupixent, which are injectable drugs that work well but require shots every two weeks. Bucket two: JAK inhibitors, which are oral pills that clear skin fast but come with serious safety warnings (think boxed labels about blood clots and cancer risk). Patients essentially choose between convenience and safety.
ENV-294 wants to be the mythical third option: a once-daily pill with the rapid skin clearance of JAK inhibitors and the clean safety profile of biologics. If that sounds too good to be true, well, the early data is surprisingly convincing.
The Numbers That Turned Heads
In an open-label trial of nine adults with moderate-to-severe eczema, patients took 800 mg of ENV-294 daily for 28 days. Researchers then watched them for another 14 days after they stopped taking the drug. By Day 42, the average patient had seen an 85% reduction in their EASI score (a standard measure of eczema severity that accounts for redness, thickness, scratching, and how much skin is affected).
Every single patient hit EASI-50, meaning at least a 50% improvement. 78% reached EASI-75, and more than half (56%) achieved EASI-90. Improvements started showing up as early as Day 8, which is remarkably quick for any eczema treatment.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Now, context matters here. Dupixent's landmark Phase 3 trials showed 44-51% of patients hitting EASI-75 at week 16. ENV-294 got 78% there in six weeks. That comparison isn't perfectly apples-to-apples (different trial sizes, designs, and patient populations), but it's the kind of gap that makes analysts lean forward in their chairs.
The Safety Sweet Spot
Impressive efficacy means nothing if your drug is a safety disaster. This is where JAK inhibitors stumbled; their speed came at the cost of boxed warnings about cardiovascular events and malignancies. Doctors have to monitor patients closely, which limits who can take them.
ENV-294 reported zero serious adverse events across all nine patients. No one dropped out. No safety signals that would require extra monitoring. For a drug going after JAK-level efficacy, that's exactly the profile you'd want to see.
Even more intriguing: one patient who had previously failed on IL4R biologics (the same class as Dupixent) achieved complete skin clearance on ENV-294. That's just one person, so don't read too much into it. But it hints that the drug might work through different enough pathways to help patients who've run out of options.
Found in Nature, Refined by AI
Enveda's backstory reads like a Silicon Valley pitch deck that somehow wandered into a biology lab. Founded in 2019 in Boulder, Colorado, the company built an AI platform called PRISM that's trained on more than a billion small-molecule mass spectra. The idea: nature has already invented millions of potential drugs through evolution, and Enveda's AI can find them faster than humans ever could.
The approach seems to be working on the discovery side, too. Enveda claims its platform produces development candidates four times faster than the industry average of 55 months. Where most companies advance roughly one in 40 chemical scaffolds to candidate status, Enveda says it converts one in four.
Investors have noticed. The company hit unicorn status in September 2025 with a $150 million Series D round that valued it at $1.2 billion. Total funding now exceeds $517 million, with backers including Premji Invest, Baillie Gifford, Lux Capital, and notably, Sanofi itself, which invested $20 million during the Series C. Yes, Dupixent's own parent company put money into a potential competitor. That's either brilliant hedging or corporate masochism.
What the Experts Are Saying
Dermatologist Jonathan Silverberg, M.D., Ph.D. of George Washington University called the data compelling, pointing to the rapid, deep responses that continued even after patients stopped taking the drug. He noted the broad pathway activity (ENV-294 modulates Th1, Th2, and Th17 pathways simultaneously) could be especially relevant for patients whose eczema isn't driven primarily by the Th2 inflammation that Dupixent targets.
Leon Kircik, M.D. of Mount Sinai highlighted the tolerability and response rates, saying the results warrant larger trials, signaling that both clinicians and Wall Street are paying attention.
The Canyon Between Here and There
Before anyone crowns ENV-294 as the Dupixent killer, let's pump the brakes. This was a nine-person, open-label study with no placebo arm. In clinical trials, that's barely a proof of concept. Patients knew they were getting the drug, which can influence both reported symptoms and the placebo effect. Open-label Phase 1b data is like a trailer for a movie; it can look amazing, but the full film might disappoint.
Dupixent's dominance was built on massive Phase 3 programs with hundreds of patients and years of real-world evidence. ENV-294 needs to replicate these early signals in its Phase 2a trial (randomized, double-blind, placebo-controlled), which is now underway. A Phase 2b is planned for mid-2026. Each step is a new hurdle, and plenty of drugs have posted spectacular early data only to stumble when the sample sizes got larger.
The atopic dermatitis market is also getting more crowded by the quarter. Multiple JAK inhibitors are already approved, and other novel mechanisms are in the pipeline. ENV-294 won't just need to beat placebo; it'll need to carve out a clear advantage over every option on the menu.
Why This Still Matters
Even with all the caveats, this data matters for three reasons. First, the oral convenience factor is enormous. Patients overwhelmingly prefer pills to injections, and doctors prefer therapies without boxed warnings. A drug that delivers on both could reshape prescribing habits overnight.
Second, the continued improvement after stopping treatment is unusual and scientifically interesting. Most eczema drugs work only while you're taking them. If ENV-294 truly modifies the disease rather than just suppressing symptoms, that's a different kind of therapy entirely.
Third, the sheer size of the prize. Atopic dermatitis is a market approaching $17 billion, and Dupixent commands the lion's share. Even capturing a slice of that pie would make ENV-294 one of the most successful AI-discovered drugs in history.
Enveda's pill has a long way to go. But for the first time in a while, Dupixent's throne doesn't look quite so comfortable.
Clinical & Regulatory4 min read
From $100M IPO to Liquidation in Five Years
IO Biotech went from a $100M IPO and "most innovative biotech" honors to total Chapter 7 liquidation in five years, all because its cancer vaccine trial missed statistical significance by the thinnest of margins. It's the most brutal cautionary tale in immuno-oncology right now.
